Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study

CorEvitas · NCT07648602

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
2500
US sites recruiting
1
Study start
June 1, 2026
Record last updated
August 26, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a 24-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be willing to be seen in-person by their treating physician for a Baseline visit (with first dose of the advanced therapy occurring within 14 days), and at 16 (+/- 5 days) and 24 weeks (+14 days) calculated based on date of first dose of the advanced therapy and must provide informed consent prior to enrolling in the study or completing study-specific questionnaires or procedures. Data will be collected from both subjects and their treating dermatology provider at predetermined scheduled intervals (Baseline, Week 16 and Week 24) using a structured and standardized data collection tool.

Being studied: Observational (Non-Interventional) Registry

Conditions: Psoriasis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

To be eligible to participate in this study, an individual must meet all the following criteria:

  • Patient is at least 18 years of age at the time of study enrollment.
  • Patient has a diagnosis of moderate to severe plaque psoriasis based on an investigator Global Assessment (IGA, score of 3 or 4 at the time of Enrollment).
  • Patient is initiating new Eligible Medication for the first time for the treatment of PSO.
  • Patient is willing and able to provide informed consent to participate in this study.

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in the study:

  • Patient is participating in a blinded clinical trial.
  • Patients that do not receive at least 1 dose of the advanced therapy within 14 days following the Enrollment/Baseline visit for the study.
  • Patients cannot be concurrently enrolled in both the CorEvitas PSO Registry and the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study. A. Patients currently enrolled in the CorEvitas PSO Registry are ineligible for participation in the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study.

B. Patients otherwise meeting eligibility criteria can be enrolled in the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study C. Following completion or at time of Exit from the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study, patients will be eligible to enroll into the CorEvitas PSO Registry for long term follow-up at the standard of care cadence supported by the registry. A separate Informed consent will be obtained.

Recruiting US locations

  • CorEvitas, LLC

    Waltham, MA 02451

    Site contact: Psoriasis Study Team · 6178655932 · ppd_corepsoriasis@thermofisher.com

Study contacts (from the official record)

  • Psoriasis Study Team · 6178655932 · ppd_corepsoriasis@thermofisher.com
All dermatology studies in Massachusetts →
PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response… (NCT07648602) | Bored Studies